Clinical Trial

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

Starton Therapeutics files patents to combine its continuous low-dose therapy, STAR-LLD, with CAR-T, aiming to enhance cancer-killing power and durability.

With no approved treatments for the deadly pregnancy complication preeclampsia, one company's novel drug is now advancing to a crucial new clinical trial.

Investors watch closely as CytoSorbents balances a push for profitability with high-stakes regulatory hurdles for its life-saving blood purification tech.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

OmniAb reported declining revenue and a wider net loss for 2025, even as it launched its revolutionary OmniUltra platform and its partners' drugs advance.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

Spryte Medical's new trial is testing a device that gives surgeons a real-time, microscopic view inside brain arteries for the first time.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

Greenwich LifeSciences' Phase III trial for its GLSI-100 immunotherapy is enrolling patients faster than ever, with early data echoing past success.

Popular weight-loss drugs are linked to fewer ER visits for chronic migraine, a new study finds, sparking hope and questions about a new treatment frontier.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.